⚠ LIVE — European Consumer Safety Watch 💊 Medicinsk kanal: 18 Under de senaste 7 dagarna 🍎 kanal.mat.label: 180 Under de senaste 7 dagarna 🧸 Produkter i kanalen: 48 Under de senaste 7 dagarna 🟢 Övervakning: EMA · RASFF · NVWA · FAGG · FAVV · EFSA · Safety Gate ⏱ Senaste hämtning: för 4 timmar sedan ⚠ LIVE — European Consumer Safety Watch 💊 Medicinsk kanal: 18 Under de senaste 7 dagarna 🍎 kanal.mat.label: 180 Under de senaste 7 dagarna 🧸 Produkter i kanalen: 48 Under de senaste 7 dagarna 🟢 Övervakning: EMA · RASFF · NVWA · FAGG · FAVV · EFSA · Safety Gate ⏱ Senaste hämtning: för 4 timmar sedan
🛡️ EUSW
🇸🇪
💊

Dabigatran etexilate Teva (previously Dabigatran etexilate Leon Farma)

dabigatran etexilate
Venös tromboembolism; Ledplastik, byte
✅ Auktoriserad Generisk
Inga aktiva aviseringar
Denna medicin har inga pågående brister, säkerhetsbrev eller återkallelser.

Vad det används till

Dabigatran etexilate Leon Farma 75 mg Primary prevention of venous thromboembolic events (VTE) in adult patients who have undergone elective total hip replacement surgery or total knee replacement surgery. Treatment of VTE and prevention of recurrent VTE in paediatric patients from birth to less than 18 years of age. Dabigatran etexilate Leon Farma 110 mg Primary prevention of venous thromboembolic events (VTE) in adult patients who have undergone elective total hip replacement surgery or total knee replacement surgery. Prevention of stroke and systemic embolism in adult patients with non-valvular atrial fibrillation (NVAF), with one or more risk factors, such as prior stroke or transient ischemic attack (TIA); age ≥ 75 years; heart failure (NYHA Class ≥ II); diabetes mellitus; hypertension. Treatment of deep vein thrombosis (DVT) and pulmonary embolism (PE), and prevention of recurrent DVT and PE in adults. Treatment of VTE and prevention of recurrent VTE in paediatric patients from birth to less than 18 years of age. Dabigatran etexilate Leon Farma 150 mg Prevention of stroke and systemic embolism in adult patients with non-valvular atrial fibrillation (NVAF), with one or more risk factors, such as prior stroke or transient ischemic attack (TIA); age ≥ 75 years; heart failure (NYHA Class ≥ II); diabetes mellitus; hypertension. Treatment of deep vein thrombosis (DVT) and pulmonary embolism (PE), and prevention of recurrent DVT and PE in adults Treatment of venous thromboembolic events (VTE) and prevention of recurrent VTE in paediatric patients from birth to less than 18 years of age.

⚠️ Patientsäkerhet

No

⚠️ Vi sammanställer officiella meddelanden. Vi lämnar ingen medicinsk rådgivning. För medicinska eller juridiska beslut, rådfråga den ansvariga myndigheten och en kvalificerad yrkesutövare.